Background: A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported. Patients and Methods: Patients with untreated measurable metastatic disease received bolus 5-Fluorouracil (600 mg/m(2)) on days 2 and 16, modulated by methotrexate (200 mg/m(2)) 24 h earlier, alternated with 4 weeks of continuous infusion of 5-Fluorouracil (200 mg/m(2)/daily) plus oxaliplatin (130 mg/m(2)) on days 29 and 56, followed by 2 weeks of rest. Serum vascular endothelial growth factor (VEGF) was analyzed at baseline and before every cycle. Results: Fifty-eight patients were enrolled. Objective remissions were reported in 45.6% (95% CI=34.3%, 57.3%). The median progression free survival was 7.8 months and the median overall survival was 19.4 months. No grade 4 toxicity was reported, except for one case of diarrhea. The serum VEGF evaluated in 23 patients showed a decreasing trend during therapy. Conclusion: The regimen was active, well tolerated and may be a possible option in patients not suitable for radical surgery.
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer / M. Zampino, K. Lorizzo, A. Rocca, M. Locatelli, L. Zorzino, S. Manzoni, C. Mazzetta, N. Fazio, R. Biffi, F. de Braud. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 26:3B(2006), pp. 2425-2428.
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer
F. de Braud
2006
Abstract
Background: A promising regimen including 5-Fluorouracil, methotrexate and oxaliplatin is reported. Patients and Methods: Patients with untreated measurable metastatic disease received bolus 5-Fluorouracil (600 mg/m(2)) on days 2 and 16, modulated by methotrexate (200 mg/m(2)) 24 h earlier, alternated with 4 weeks of continuous infusion of 5-Fluorouracil (200 mg/m(2)/daily) plus oxaliplatin (130 mg/m(2)) on days 29 and 56, followed by 2 weeks of rest. Serum vascular endothelial growth factor (VEGF) was analyzed at baseline and before every cycle. Results: Fifty-eight patients were enrolled. Objective remissions were reported in 45.6% (95% CI=34.3%, 57.3%). The median progression free survival was 7.8 months and the median overall survival was 19.4 months. No grade 4 toxicity was reported, except for one case of diarrhea. The serum VEGF evaluated in 23 patients showed a decreasing trend during therapy. Conclusion: The regimen was active, well tolerated and may be a possible option in patients not suitable for radical surgery.File | Dimensione | Formato | |
---|---|---|---|
2425.full.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
67.84 kB
Formato
Adobe PDF
|
67.84 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.